Fietz, Simon
Zarbl, Romina
Niebel, Dennis
Posch, Christian
Brossart, Peter
Gielen, Gerrit H.
Strieth, Sebastian
Pietsch, Torsten
Kristiansen, Glen
Bootz, Friedrich
Landsberg, Jennifer
Dietrich, Dimo http://orcid.org/0000-0001-9794-7927
Funding for this research was provided by:
BONFOR program of the University Hospital Bonn (O-105.0069)
DFG Cluster of Excellence ImmunoSensation (EXC 1023)
Universitätsklinikum Bonn
Article History
Received: 23 July 2020
Accepted: 20 October 2020
First Online: 16 November 2020
Compliance with ethical standards
:
: JS is a consultant/advisory board member and received speaker’s honoraria from Novartis, BMS, MSD, and Roche. DN has received speakers’ honoraria or travel expense reimbursements from the following companies: BMS, Novartis, GSK, Celgene, and MSD. JL is a consultant/advisory board member and received speaker’s honoraria from Novartis, BMS, MSD, and Roche. DD owns patents and patent applications on biomarker technologies and methylation of immune checkpoint genes as predictive and prognostic biomarkers. The patents are licensed to Qiagen GmbH (Hilden, Germany). DD is a consultant for AJ Innuscreen GmbH (Berlin, Germany) and receives royalties from product sales. The other authors have declared that no conflict of interest exists.
: Our study was approved by the Institutional Review Board (IRB) of the University Hospital Bonn (vote no. 187/16).
: The ethics committee waived the requirement to obtain informed consent.